Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach.
Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach.
复制标题
DOI：
10.1200/edbk_389942
复制
发表时间：
2023-06-01
期刊：
影响因子：
--
通讯作者：
Baracos, Vickie E
中科院分区：
文献类型：
--
作者：
Kadakia, Kunal C;Hamilton-Reeves, Jill M;Baracos, Vickie E
近年来，我们对癌症恶病质的认识取得了重大进展。尽管取得了这些进展，但没有药物获得美国食品和药物管理局批准用于这种常见且高度病态的综合征。幸运的是，对癌症恶病质分子基础的进一步理解已经导致了处于药物开发不同阶段的新的靶向方法。本文综述了两个主要的主题领域，推动这些药理学策略，包括那些针对信号介质在中枢神经系统和骨骼肌的水平。此外，正在测试药理学策略与靶向营养素、营养疗法和运动相结合来治疗癌症恶病质。为此，我们强调最近发表的和正在进行的试验评估癌症恶病质治疗在这些特定领域。
Significant progress in our understanding of cancer cachexia has occurred in recent years. Despite these advances, no pharmacologic agent has achieved US Food and Drug Administration approval for this common and highly morbid syndrome. Fortunately, improved understanding of the molecular basis of cancer cachexia has led to novel targeted approaches that are in varying stages of drug development. This article reviews two major thematic areas that are driving these pharmacologic strategies, including those targeting signal mediators at the level of the CNS and skeletal muscle. Additionally, pharmacologic strategies are being tested in combination with targeted nutrients, nutrition therapy, and exercise to treat cancer cachexia. To this end, we highlight recently published and ongoing trials evaluating cancer cachexia therapies in these specific areas.